Reshma Kewalramani. Vertex
October 28, 2019 10:45 AM EDTUpdated October 29, 07:41 AM
Deals

A deal-hun­gry Ver­tex ush­ers in three more gene edit­ing pro­grams as it clos­es out har­bin­ger CRISPR deal

Amber Tong

Back in 2015, Ver­tex made a splash in the nascent CRISPR gene edit­ing world by wa­ger­ing $105 mil­lion to part­ner with one of its pi­o­neers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times